LIPS-A: Lung Injury Prevention Study With Aspirin
The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.
Stanford is now accepting new patients for this trial.
- drug : Lactose powder
- drug : Aspirin
Phase: Phase 2
Ages Eligible For Study:
- Adult patients (age > 18) admitted to the hospital through the emergency department (ED) - At high risk of developing acute lung injury (ALI) Lung Injury Prediction Score (LIPS) greater than or equal to 4